HMPL-453

DRUG7 trials

Sponsors

Hutchison Medipharma Limited, Hutchmed

Conditions

Advanced Intrahepatic CholangiocarcinomaAdvanced Malignant MesotheliomaIntrahepatic CholangiocarcinomaMass Balance StudySolid TumorSolid Tumor, Adult

Phase 1

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

TerminatedNCT02966171

Hutchison Medipharma LimitedSolid Tumor

Start: 2017-01-31End: 2018-08-23Updated: 2018-11-21

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Hutchison Medipharma LimitedSolid Tumor, Adult

Start: 2017-05-23End: 2020-06-30Updated: 2020-02-13

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

CompletedNCT05173142

Hutchison Medipharma LimitedSolid Tumor

Start: 2022-01-22End: 2026-01-17Updated: 2026-05-15

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

CompletedNCT05930119

HutchmedIntrahepatic Cholangiocarcinoma

Start: 2023-03-17End: 2023-08-28Updated: 2023-09-06

Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects

CompletedNCT07644442

HutchmedMass Balance Study

Start: 2025-02-26End: 2025-03-14Updated: 2026-06-12

Phase 2

HMPL-453 in Advanced Malignant Mesothelioma

Hutchison Medipharma LimitedAdvanced Malignant Mesothelioma

Start: 2019-12-30End: 2023-03-17Target: 27Updated: 2020-06-16

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

RecruitingNCT04353375

HutchmedAdvanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult

Start: 2020-09-03End: 2030-02-28Target: 235Updated: 2025-12-31

Related Papers

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.

2024-07-095 citations

A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.

Journal of Clinical Oncology2023-06-011 citations

Abstract 6321: HMPL-453, a highly selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays potent activity in FGFR-altered tumor models

Cancer Research2023-04-041 citations